Dr. Zhenping Zhu is the President of Research and Development, Chief Scientific Office, at 3SBio Inc. Prior to joining 3SBio, he was Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation (New York), and President of Kadmon China. Prior to joining Kadmon, Dr. Zhu was Vice President and Global Head, Protein Sciences and Design, at Novartis, where he led research groups globally in Basel (Switzerland), Cambridge (US), and Shanghai (China), and was responsible for the discovery, design and selection of novel biologics medicines that address various human diseases. Dr. Zhu worked for over 12 years at ImClone Systems (New York) as Vice President of Antibody Technology and Immunology, and has led teams that successfully discovered and developed several FDA-approved novel antibodies for multiple oncology indications, including cetuximab (Erbitux^R), ramucirumab (Cyramza^R), necitumumab (Portrazza^R), and olaratumab (Lartruvo^R). Dr. Zhu is the inventor of both ramucirumab and necitumumab, and a major contributor to cetuximab and olaratumab.

Dr. Zhu earned his medical degree from Jiangxi Medical College (Nanchang, China), passed USMLE and is certified by US ECFMG. He received his MSc in Pharmacology from the Institute of Hematology, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) (Beijing, China), and his PhD in Immunology and Pathology from Dalhousie University (Halifax, Canada). Dr. Zhu performed his postdoctoral work in antibody/protein engineering at Genentech Inc. (South San Francisco, CA). From 1996 to 2006, Dr. Zhu held an adjunct professorship at the Institute of Hematology, CAMS & PUMC. Dr. Zhu has been working in the field of antibody therapeutics for over 30 years, including 24 years of research and management experience in global biopharmaceutical industry. He has published over 190 peer-reviewed scientific papers, and is listed as the inventor or co-inventor of more than 100 US and international patents and patent applications.